Quantum Biopharma Ltd. Files October 2025 6-K Report

Ticker: QNTM · Form: 6-K · Filed: Oct 14, 2025 · CIK: 1771885

Quantum Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyQuantum Biopharma Ltd. (QNTM)
Form Type6-K
Filed DateOct 14, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer, company-update

TL;DR

Quantum Biopharma (fka FSD Pharma) filed its October 6-K, confirming 20-F annual filings.

AI Summary

Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on October 14, 2025. The company, incorporated in A6 with its principal executive offices in Toronto, Ontario, is reporting as a foreign private issuer. This filing is for the month of October 2025 and indicates the company files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Quantum Biopharma's status as a foreign private issuer and its reporting practices.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information.

Key Players & Entities

  • Quantum Biopharma Ltd. (company) — Filer of the 6-K report
  • FSD Pharma Inc. (company) — Former name of Quantum Biopharma Ltd.
  • October 14, 2025 (date) — Filing date of the 6-K report
  • Toronto, Ontario (location) — Location of principal executive offices
  • Form 20-F (document) — Annual report form filed by the company
  • Form 6-K (document) — Type of report being filed

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report information for the month of October 2025 as required by the U.S. Securities and Exchange Commission for foreign private issuers.

What was Quantum Biopharma Ltd.'s former name?

Quantum Biopharma Ltd.'s former name was FSD Pharma Inc., with a date of name change on March 27, 2019.

Where are Quantum Biopharma Ltd.'s principal executive offices located?

Quantum Biopharma Ltd.'s principal executive offices are located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9.

Does Quantum Biopharma Ltd. file annual reports under Form 20-F or Form 40-F?

Quantum Biopharma Ltd. files annual reports under cover of Form 20-F, as indicated by the checkmark in the filing.

What is the SIC code for Quantum Biopharma Ltd.?

The Standard Industrial Classification (SIC) code for Quantum Biopharma Ltd. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2025-10-14 08:15:03

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: October 14, 2025 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated October 14, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.